凯谊商贸计划自公告披露之日起15个交易日后的3个月内（2025年7月23日至2025年10月22日，此期间如 遇法律、法规规定的窗口期则不减持），通过集中竞价交易或大宗交易方式合计减持公司股份不超过 10,460,000股（占公司总股本比例不超过的1%）。 中国经济网北京7月2日讯 上海凯宝（300039）(300039.SZ)昨日晚间发布公告称，公司于近日收到控股 股东、实际控制人穆竟伟的一致行动人新乡市凯谊商贸有限公司（以下简称"凯谊商贸"）出具的《关于 股份减持计划的告知函》。 | | 2024 年 | 2023 年 | 本年比上年增减 | 2022年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 1, 473, 319, 046. 15 | 1,594,051, 470. 75 | -7.57% | 1,118,850,525.24 | | 归属于上市公司股东 的净利润(元) | 375,578,025,27 | 327,870,830,14 | 14. 55% | 190,804,507.54 | | 归属于上市公司股东 的扣除非经常性损益 的净利润(元 ...

Group 1 - *ST San Sheng (002742.SZ): The controlling shareholder Pan Xianwen's judicial auction of 32.2 million shares has been completed, with 30 million shares transferred, accounting for 6.94% of the total share capital. After the reduction, Pan Xianwen's shareholding ratio decreased from 24.20% to 17.26%, which will not lead to a change in company control [1] - Aike Co., Ltd. (300889.SZ): Shareholder Zhang Fengbin, holding over 5%, reduced his stake by 1% (1.67818 million shares) from May 13 to June 27, 2025, bringing his holding to 7.9902% [1] - Anlu Technology (688107.SH): The shareholder National Integrated Circuit Industry Investment Fund Co., Ltd. completed its reduction plan, selling 4.008493 million shares (1% of total share capital) from May 8 to June 30, 2025, with a total reduction amount of 109.36 million yuan, current holding ratio at 5.76% [1] Group 2 - Anshuo Information (300380.SZ): The controlling shareholder Shanghai Anshuo Technology Development Co., Ltd. and actual controllers reduced their stakes by 1.16% (1.599416 million shares), 0.94% (1.300187 million shares), and 0.65% (900,000 shares) respectively [1] - Baoming Technology (002992.SZ): Directors and management plan to reduce their holdings by a total of 0.0107%, 0.0714%, and 0.0107% over the next three months [2] - Beiyikang (870199.BJ): Employee shareholding platforms completed their reduction plans, selling 546,284 shares (0.8%) and 131,650 shares (0.19%) [2] Group 3 - Boyun New Materials (002297.SZ): Major shareholder Hunan Xiangtou High-tech Venture Capital Co., Ltd. reduced its stake by 406.74 million shares (0.71%) from June 5 to June 30, 2025, bringing its holding to 6.99% [2] - Dongwei Technology (688700.SH): Specific shareholder Xie Yulong completed a reduction plan, selling 574,857 shares (0.1927%) from June 4 to June 30, 2025, with a total reduction amount of 21.362156 million yuan, current holding ratio at 0% [2] - Fuzhi Environmental Protection (688335.SH): Major shareholder Deqing Junjie Enterprise Management Partnership plans to reduce up to 4.441035 million shares (3%) over the next three months [3] Group 4 - Gu Gao Technology (301510.SZ): Shareholder Beijing Equity Investment Development Management Center completed its reduction plan, selling 4.0001 million shares (1%) from June 5 to June 30, 2025, bringing its holding to 7.68% [3] - Guangbo Co., Ltd. (002103.SZ): Shareholder Ren Hangzhong reduced his stake by 156,440 shares (0.2928%), bringing his holding to 9.99999% [3] - Guoke Military Industry (688543.SH): Specific shareholders Yang Minghua and Chen Gonglin plan to reduce up to 2.08842 million shares (1%) and 3.789115 million shares (1.8143%) over the next three months [3] Group 5 - Guorui Technology (300600.SZ): Major shareholder Gong Ruiliang reduced his stake by 3.243209 million shares (1.1%) from June 27 to July 1, 2025, bringing his holding to 20.63% [4] - Hangzhou Thermal Power (605011.SH): Shareholder Huashi Investment plans to reduce up to 5.997 million shares (1.4989%) over the next three months [4] - Huaya Intelligent (003043.SZ): Executives plan to reduce their holdings by a total of 0.0132%, 0.0092%, and 0.0092% over the next three months [4]

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

证券代码：300039 证券简称：上海凯宝 公告编号：2025-031 上海凯宝药业股份有限公司关于公司 控股股东、实际控制人的一致行动人减持股份的预披露公告 公司控股股东、实际控制人的一致行动人新乡市凯谊商贸有限公司保证向本公 司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 截至本公告披露日，上海凯宝药业股份有限公司（以下简称"公司"或"本公 司"）控股股东、实际控制人穆竟伟的一致行动人新乡市凯谊商贸有限公司（以下 简称"凯谊商贸"）持有公司股份 78,425,019 股（占公司总股本比例 7.50%），穆 竟伟及其一致行动人张艳琪、穆竟男、凯谊商贸合计持有公司 415,455,841 股（占 公司总股本比例 39.72%）股份。 公司于近日收到控股股东、实际控制人的一致行动人凯谊商贸出具的《关于股 份减持计划的告知函》。凯谊商贸计划自本公告披露之日起 15 个交易日后的 3 个月 内（2025 年 7 月 23 日至 2025 年 10 月 22 日，此期间如遇法律、法规规定的窗口期 则不减持），通过集 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

上海凯宝(300039.SZ)公告称，近日收到国家药品监督管理局签发的痰热清胶囊《药品注册证书》，新 增适应症"在新型冠状病毒感染的常规治疗中，可用于轻型引起的发热、咳嗽、咽痛等。"痰热清胶囊为 公司品种，此次获批将进一步扩大产品适用范围，提升市场竞争力及品牌知名度。但药品销售情况可能 受到国家政策、市场环境变化等多种因素影响，存在不确定性。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"、"上海凯宝"）近日收到国家 药品监督管理局签发的痰热清胶囊《药品注册证书》。具体情况如下： | 药品名称 | 痰热清胶囊 | | --- | --- | | 剂型 | 胶囊剂 | | 规格 | 每粒装 0.4g（相当于饮片 2.98g） | | 包装规格 | 每板装 9 粒，每盒装 2 板 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 中药 2.3 类 | | 药品有效期 | 24个月 | | 处方药/非处方药 | 处方药 | | 证书编号 | 2025S01970 | | 药品批准文号 | 国药准字 Z20130025 | | 药品注册标准编号 | YBZ00522025 | | 上市许可持有人 | 上海凯宝药业股份有限公司 | 一、药品的基本情况 证券代码：300039 证券简称：上海凯宝 公告编号：2025-030 上海凯宝药业股份有限公司 关于获得药品注册证书的公告 痰热清胶囊为公司主营产品痰热清系列产品之一，是公司独家品种，功能主治： 清热 ...

上海凯宝药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股东大会审议通过权益分派方案的相关情况 1．上海凯宝药业股份有限公司（以下简称"本公司"）2024 年年度权益分派 方案已获 2025 年 5 月 16 日召开的 2024 年年度股东大会审议通过，2024 年度利润 分配预案为：以公司总股本 1,046,000,000 股为基数，向全体股东每 10 股派发人民 币现金红利 1.00 元（含税）。其余未分配利润结转下年。如在本公告披露之日起至 实施权益分派股权登记日前，公司总股本发生变动的，公司将按照分配总额不变的 原则对分配比例进行调整。具体内容详见公司在巨潮资讯网上披露的相关公告。 2．本次分配方案自披露之日起至实施期间公司股本总额未发生变化。本次实施 的分配方案与股东大会审议通过的分配方案一致。 3.本次分红派息距离股东大会审议通过的时间未超过两个月。 二、权益分派方案 证券代码：300039 证券简称：上海凯宝 公告编号：2025-029 五、权益分派方法 本公司 2024 年年度权益分派方案 ...

上海市通力律师事务所 关于上海凯宝药业股份有限公司 2024 年年度股东大会的法律意见书 致: 上海凯宝药业股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海凯宝药业股份有限公司(以下简称 "公司")的委托, 指派本所黄新淏律师、徐安昌律师(以下简称"本所律师")根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规范性 文件(以下统称"法律法规")及《上海凯宝药业股份有限公司章程》(以下简称"公司章程") 的规定就公司 2024 年年度股东大会(以下简称"本次股东大会")相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有签 署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和有效 的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见, 并 不对 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2025-028 上海凯宝药业股份有限公司 特别提示： 1．本次股东大会未出现否决议案的情形； 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议的召开情况 1.会议召开的日期、时间： （1）现场会议时间：2025 年 5 月 16 日（周五）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 16 日上午 9:15-9:25、9:30-11:30 和 13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2025 年 5 月 16 日上午 9：15 至下午 15:00 期 间的任意时间。 2024 年年度股东大会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2.现场会议地点：上海市工业综合开发区程普路 88 号公司三楼会议室 3.会议召开方式：以现场投票和网络投票相结合的方式召开 4.会议的召集人：公司董事会 5.会议的主持人：董事长穆竟伟女士 6.本次会议的召集、召开和表决程序符合 ...